Release of anti-HIV mediators after administration of leukotriene B 4 to humans

Journal of Infectious Diseases

Volumn 189, Issue 11, 2004, Pages 2001-2009

  Flamand, Louis ^a   Borgeat, Pierre ^a   Lalonde, Richard ^b   Gosselin, Jean ^a  

^a LAVAL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ANTIGEN; CD63 ANTIGEN; CD66B ANTIGEN; INTERLEUKIN 8; LEUKOTRIENE B4 DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGRANULATION; DISEASE MARKER; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IN VITRO STUDY; LEUKOCYTE ACTIVATION; NEUTROPHIL CHEMOTAXIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ALPHA-DEFENSINS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CHEMOTAXIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-8; LEUKOTRIENE B4; MACROPHAGE INFLAMMATORY PROTEIN-1; NEUTROPHILS; PLATELET MEMBRANE GLYCOPROTEINS;

EID: 2542467586     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/386374     Document Type: Article

References (50)

1. + T cells. Science 1995; 270:1811-5.
2. Zhang L, Yu W, He T, et al. Contribution of human α-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002; 298:995-1000.
3. Mackewicz CE, Yuan J, Tran P, et al. α-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 2003; 17:F23-32.
4. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol 2002; 14:96-102.
5. Nakashima H, Yamamoto N, Masuda M, Fujii N. Defensins inhibit HIV replication in vitro. AIDS 1993; 7:1129.
6. Bastian A, Schafer H. Human α-defensin 1 (HNP-1) inhibitsadenoviral infection in vitro. Regul Pept 2001; 101:157-61.
7. Sinha S, Cheshenko N, Lehrer RI, Herold BC. NP-1, a rabbit α-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. Antimicrob Agents Chemother 2003; 47:494-500.
8. Ganz T, Selsted ME, Szklarek D, et al. Defensins: natural peptide antibiotics of human neutrophils. J Clin Invest 1985; 76:1427-35.
9. Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J Virol 1986; 60:1068-74.
10. Chang TL, Francois F, Mosoian A, Klotman ME. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from α-defensin-1 HIV inhibition. J Virol 2003; 77:6777-84.
11. Ko HJ, Lim SS. Production of macrophage inflammatory protein (MIP)-1α and MIP-1β by human polymorphonuclear neutrophils stimulated with Porphyromonas endodontalis lipopolysaccharide. J Endod 2002; 28:754-7.
12. Lapinet JA, Scapini P, Calzetti F, Perez O, Cassatella MA. Gene expression and production of tumor necrosis factor-α, interleukin-1β (IL-1β), IL-8, macrophage inflammatory protein 1α (MIP-1α), MIP-1β, and gamma interferon-inducible protein 10 by human neutrophils stimulated with group B meningococcal outer membrane vesicles. Infect Immun 2000; 68:6917-23.
13. Bliss SK, Marshall AJ, Zhang Y, Denkers EY. Human polymorphonuclear leukocytes produce IL-12, TNF-α, and the chemokines macrophage- inflammatory protein-1α and -1β in response to Toxoplasma gondii antigens. J Immunol 1999; 162:7369-75.
14. Ellis M, Gupta S, Galant S, et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis 1988; 158:1268-76.
15. Meddows-Taylor S, Martin DJ, Tiemessen CT. Reduced expression of interleukin-8 receptors A and B on polymorphonuclear neutrophils from persons with human immunodeficiency virus type 1 disease and pulmonary tuberculosis. J Infect Dis 1998; 177:921-30.
16. Valone FH, Payan DG, Abrams DI, Goetzl EJ. Defective polymorphonuclear leukocyte chemotaxis in homosexual men with persistent lymph node syndrome. J Infect Dis 1984; 150:267-71.
17. Lazzarin A, Uberti Foppa C, Galli M, et al. Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome. Clin Exp Immunol 1986; 65:105-11.
18. Shalekoff S, Tiemessen CT, Gray CM, Martin DJ. Depressed phagocytosis and oxidative burst in polymorphonuclear leukocytes from individuals with pulmonary tuberculosis with or without human immunodeficiency virus type 1 infection. Clin Diagn Lab Immunol 1998; 5:41-4.
19. 4 associated with AIDS. AIDS 1989; 3:651-3.
20. Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J Clin Invest 1998; 102:663-70.
21. Coffey MJ, Phare SM, Kazanjian PH, Peters-Golden M. 5-Lipoxygenase metabolism in alveolar macrophages from subjects infected with the human immunodeficiency virus. J Immunol 1996; 157:393-9.
22. 4. Biochem Biophys Res Commun 1991; 178:302-8.
23. Borgeat P, Samuelsson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes: formation of a novel dihydroxyeicosatetraenoic acid. J Biol Chem 1979; 254:2643-6.
24. 4 receptor: cloning and functional characterization. J Biol Chem 2000; 275:40686-94.
25. 4 that mediates chemotaxis. Nature 1997; 387:620-4.
26. 4 receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med 2000; 192:421-32.
27. 4 on the adhesive kinetics of LFA-1 and Mac-1 on human neutrophils. Am J Physiol Cell Physiol 2001; 281:C1568-78.
28. Zimmerman BJ, Holt JW, Paulson JC, et al. Molecular determinants of lipid mediator-induced leukocyte adherence and emigration in rat mesenteric venules. Am J Physiol 1994; 266:H847-53.
29. 4 augments interleukin-2 receptor-β (IL-2Rβ) expression and IL-2Rβ-mediated cytotoxic response in human peripheral blood lymphocytes. Immunology 1992; 76:258-63.
30. 4 mediated by enhanced effector-target cell binding and increased lytic efficiency. Cell Immunol 1987; 110:243-52.
31. 4 enhances activation, proliferation, and differentiation of human B lymphocytes. J Immunol 1989; 143:1996-2000.
32. 4 potentiates the expression and release of Fc epsilon RII/CD23, and proliferation and differentiation of human B lymphocytes induced by IL-4. J Immunol 1990; 145:3406-11.
33. Chen N, Restivo A, Reiss CS. Leukotrienes play protective roles early during experimental VSV encephalitis. J Neuroimmunol 2001; 120:94-102.
34. 4. Clin Exp Immunol 2001; 126:494-502.
35. van Strijp JA, van Kessel KP, van der Tol ME, Fluit AC, Snippe H, Verhoef J. Phagocytosis of herpes simplex virus by human granulocytes and monocytes. Arch Virol 1989; 104:287-98.
36. Maltezou HC, Kafetzis DA, Abisaid D, Mantzouranis EC, Chan KW, Rolston KV. Viral infections in children undergoing hematopoietic stem cell transplant. Pediatr Infect Dis J 2000; 19:307-12.
37. Tumpey TM, Chen SH, Oakes JE, Lausch RN. Neutrophil-mediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea. J Virol 1996; 70:898-904.
38. Watanabe D, Adachi A, Tomita Y, Yamamoto M, Kobayashi M, Nishiyama Y. The role of polymorphonuclear leukocyte infiltration in herpes simplex virus infection of murine skin. Arch Dermatol Res 1999; 291:28-36.
39. Milligan GN, Bourne N, Dudley KL. Role of polymorphonuclear leukocytes in resolution of HSV-2 infection of the mouse vagina. J Reprod Immunol 2001; 49:49-65.
40. Fujisawa H. Inhibitory role of neutrophils on influenza virus multiplication in the lungs of mice. Microbiol Immunol 2001; 45:679-88.
41. Mastroianni CM, Lichtner M, Mengoni F, et al. Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. AIDS 1999; 13:883-90.
42. Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003; 36:789-94.
43. Morris A, Wachter RM, Luce J, Turner J, Huang L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17:73-80.
44. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15:347-55.
45. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-64.
46. Scozzafava A, Mastrolorenzo A, Supuran CT. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J Enzyme Inhib Med Chem 2002; 17:69-76.
47. Canny G, Levy O, Furuta GT, et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci USA 2002; 99:3902-7.
48. 4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 2003; 4:965-73.
49. 4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003; 4:982-90.
50. 4. Nat Immunol 2003; 4:974-81.